Eli Lilly and Company (NYSE:LLY) Shares Sold by Paulson Wealth Management Inc.

Paulson Wealth Management Inc. trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,049 shares of the company’s stock after selling 20 shares during the quarter. Paulson Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $816,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LLY. Simon Quick Advisors LLC increased its stake in Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares during the period. Independent Advisor Alliance increased its stake in Eli Lilly and Company by 1.7% in the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock valued at $18,810,000 after buying an additional 544 shares during the period. Apexium Financial LP increased its stake in Eli Lilly and Company by 1,819.1% in the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock valued at $6,667,000 after buying an additional 10,842 shares during the period. Clear Harbor Asset Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $363,000. Finally, Terril Brothers Inc. increased its stake in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after buying an additional 429 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LLY. Morgan Stanley reissued an “overweight” rating and issued a $1,023.00 price objective on shares of Eli Lilly and Company in a research note on Friday, July 5th. Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $850.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Thursday. Argus boosted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Finally, Barclays boosted their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $843.00.

Eli Lilly and Company Price Performance

LLY stock traded down $10.92 during trading on Thursday, hitting $928.86. The stock had a trading volume of 1,887,935 shares, compared to its average volume of 2,929,181. The company’s 50 day moving average price is $841.60 and its two-hundred day moving average price is $758.80. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $945.69. The stock has a market cap of $882.80 billion, a price-to-earnings ratio of 136.88, a price-to-earnings-growth ratio of 2.00 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the previous year, the company posted $1.62 EPS. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, sell-side analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 93,593 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $918.64, for a total value of $85,978,273.52. Following the completion of the transaction, the insider now owns 97,153,810 shares in the company, valued at approximately $89,249,376,018.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 93,593 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $918.64, for a total value of $85,978,273.52. Following the completion of the transaction, the insider now owns 97,153,810 shares in the company, valued at approximately $89,249,376,018.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the transaction, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders sold a total of 1,004,704 shares of company stock worth $869,479,116 in the last 90 days. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.